Cutoff for Malignancy for Pancreatic Neuroendocrine Tumors Could Be Decreased

Share this content:
The cutoff of 2 cm of malignancy used for small nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) could be reduced.
The cutoff of 2 cm of malignancy used for small nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) could be reduced.

The cutoff of 2 cm of malignancy used for small nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) could be reduced to 1.7 cm to select patients more accurately, a new study published in the journal Surgery has shown.1

Because there is no clear consensus on the management of NF-PNETs 2 cm or smaller, researchers sought to determine the prognostic value of indicators of malignancy in sporadic NF-PNETs of that size.

Researchers retrospectively analyzed data from 80 patients treated at 7 French University Hospital Centers who were managed by operative resection or observational follow-up. All PNETs were ranked using the European Neuroendocrine Tumor Society grading system and a total of 15 patients had malignant tumor as defined by node or live metastasis.

Results showed that the median disease-free survival was 16 months for malignant PNETs and 30 months for nonmalignant PNETs. Researchers found that tumor size had a significant impact on malignancy. Specifically, a tumor size cutoff of 1.7 cm was found to predict malignancy with 92% sensitivity and 75% specificity.

RELATED:  Pazopanib Shows Clinical Activity in Advanced Neuroendocrine Tumors

PNETs form in islet cells of the pancreas and may be functioning or nonfunctioning, meaning that they either produce extra hormones or they do not. Most PNETs are functional tumors but most nonfunctional PNETs are malignant.2

Reference

  1. Regenet N, Carrere N, Boulanger G, et al. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study [published online ahead of print November 14, 2015]. Surgery. doi: 10.1016/j.surg.2015.10.003.
  2. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®). National Cancer Institute website. http://www.cancer.gov/types/pancreatic/patient/pnet-treatment-pdq. Updated July 30, 2015. Accessed November 19, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters